Opioid and benzodiazepine prescribing after COVID-19 hospitalization.
J Hosp Med
; 17(7): 539-544, 2022 07.
Article
in English
| MEDLINE | ID: covidwho-1866544
ABSTRACT
Opioid and benzodiazepine prescribing after COVID-19 hospitalization is not well understood. We aimed to characterize opioid and benzodiazepine prescribing among naïve patients hospitalized for COVID and to identify the risk factors associated with a new prescription at discharge. In this retrospective study of patients across 39 Michigan hospitals from March to November 2020, we identified 857 opioid- and benzodiazepine-naïve patients admitted with COVID-19 not requiring mechanical ventilation. Of these, 22% received opioids, 13% received benzodiazepines, and 6% received both during the hospitalization. At discharge, 8% received an opioid prescription, and 3% received a benzodiazepine prescription. After multivariable adjustment, receipt of an opioid or benzodiazepine prescription at discharge was associated with the length of inpatient opioid or benzodiazepine exposure. These findings suggest that hospitalization represents a risk of opioid or benzodiazepine initiation among naïve patients, and judicious prescribing should be considered to prevent opioid-related harms.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
/
Analgesics, Opioid
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Hosp Med
Year:
2022
Document Type:
Article
Affiliation country:
Jhm.12842
Similar
MEDLINE
...
LILACS
LIS